Meeting
2022 ASCO Annual Meeting
Immune checkpoint inhibitor–induced diabetes mellitus across NCI trials.
Authors
Zoe E. Quandt
University of California-San Francisco, Division of Endocrinology, San Francisco, CA
Zoe E. Quandt , Vanessa Hill , Joe E. Dib , Jason Burian , Sapir Tessler , Abdul Rafeh Naqash , Mark S Anderson , Megan Othus , Elad Sharon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2668)
DOI
10.1200/JCO.2022.40.16_suppl.2668
Abstract #
2668
Poster Bd #
322
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Uncontrolled diabetes mellitus and the progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans.
First Author: Lawrence Liu
Poster
2021 ASCO Annual Meeting
Pan-Canadian cohort of immune checkpoint inhibitor-induced insulin-dependent diabetes mellitus (CANDIED).
First Author: Thiago Pimentel Muniz
First Author: Rebecca Jeun
Poster
2020 Gastrointestinal Cancers Symposium
Changes in glucose tolerance after pancreatectomy in patients with pancreatic ductal adenocarcinoma.
First Author: Sachiyo Shirakawa